Dr. Gang Lin

Structural insights into a potent antimalarial drug candidate’s interaction with the malaria parasite Plasmodium falciparum have paved the way for drug-resistant malaria therapies, according to a new study by researchers at Weill Cornell Medicine and Van Andel Institute.

The second annual Dean’s Symposium on Opportunities for Entrepreneurship and Academic Drug Development highlighted the resources available to Weill Cornell Medicine investigators to help them turn their research findings into new treatments and therapies for patients.

Seven winners have been selected for the third round of the Daedalus Fund for Innovation awards, an innovative Weill Cornell Medicine program that helps advance promising applied and translational research projects and emerging technologies that have commercial potential.